文献速递新生儿儿童内分泌与遗传代谢

新生儿重症监护病房中抢先药物基因组学分型的潜在影响

The Potential Impact of Preemptive Pharmacogenetic Genotyping in the Neonatal Intensive Care Unit.
PubMed 文献 · J Pediatr · 2023-05-17

该回顾性观察研究纳入2005至2018年接受新生儿重症监护且5岁后至少有一次再住院的4196例患者,评估临床药物遗传学实施联盟(CPIC)指南相关药物在早期儿童的暴露情况。结果显示67%暴露于1-2种、28%暴露于3-4种、5%暴露于5种及以上PGx药物;早产、低出生体重(<2500 g)及先天畸形和/或原发遗传诊断是CPIC药物暴露的显著预测因素(P < .01)。结论认为NICU抢先PGx检测可能对NICU期间及整个早期儿童期的医疗管理产生显著影响。

要点

  • NICU患儿在早期儿童期普遍暴露于CPIC指南相关药物,67%暴露1-2种、28%暴露3-4种、5%暴露5种及以上。
  • 早产、低出生体重(<2500 g)及先天畸形和/或原发遗传诊断是CPIC药物暴露的显著预测因素(P < .01)。
  • 抢先PGx检测可能对NICU住院期间及早期儿童期的医疗管理产生显著影响。

核心结论

  • 在NICU患者中进行抢先PGx检测可能对NICU住院期间及整个早期儿童期的医疗管理产生显著影响。

研究设计与样本

  • 收集住院、药物暴露、胎龄、出生体重、先天畸形和/或原发遗传诊断等数据,确定PGx药物及药物类别暴露发生率并分析预测因素。

主要发现

  • 67%的纳入患者在早期儿童期接受1-2种PGx药物,28%接受3-4种,5%接受5种及以上。
  • 早产、低出生体重(<2500 g)及存在任何先天畸形和/或原发遗传诊断是CPIC药物暴露的显著预测因素(P < .01,P < .01,P < .01)。

关键数值与推荐

  • PGx药物依据临床药物遗传学实施联盟(CPIC)指南界定。
  • 低出生体重定义为<2500 g。
  • 早产、低出生体重(<2500 g)及先天畸形和/或原发遗传诊断预测CPIC药物暴露的P值均< .01。

临床怎么用

  • 对NICU患儿,尤其早产、低出生体重(<2500 g)或存在先天畸形和/或原发遗传诊断者,可考虑抢先PGx检测以指导NICU期间及早期儿童期的用药管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the use of drugs with pharmacogenomic (PGx) guidelines from the Clinical Pharmacogenetics Implementation Consortium in early childhood. STUDY DESIGN: A retrospective observational study of patients admitted to the neonatal intensive care (NICU) between 2005 and 2018 with at least 1 subsequent hospitalization at or after 5 years of age was performed to determine PGx drug exposure. Data regarding hospitalizations, drug exposures, gestational age, birth weight, and congenital anomalies and/or a primary genetic diagnosis were collected. Incidence of PGx drug and drug class exposures was determined and patient specific factors predictive of exposure were investigated. RESULTS: During the study, 19 195 patients received NICU care and 4196 (22%) met study inclusion; 67% received 1-2, 28% 3-4, and 5% 5 or more PGx-drugs in early childhood. Preterm gestation, low birth weight (<2500 g), and the presence of any congenital anomalies and/or a primary genetic diagnosis were statistically significant predictors of Clinical Pharmacogenetics Implementation Consortium drug exposures (P < .01, P < .01, P < .01, respectively). CONCLUSIONS: Preemptive PGx testing in patients in the NICU could have a significant impact on medical management during the NICU stay and throughout early childhood.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Gallaway KA, Cann K, Oetting K, et al. The Potential Impact of Preemptive Pharmacogenetic Genotyping in the Neonatal Intensive Care Unit. J Pediatr. 2023. PMID: 37201679. doi:10.1016/j.jpeds.2023.113489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。